(EUZ) Eckert & Ziegler Strahlen - Ratings and Ratios
Seeds, Applicators, Generators, Isotopes, Irradiators
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.28% |
| Yield on Cost 5y | 3.98% |
| Yield CAGR 5y | 51.02% |
| Payout Consistency | 78.3% |
| Payout Ratio | 10.2% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 39.9% |
| Value at Risk 5%th | 56.1% |
| Relative Tail Risk | -14.68% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.25 |
| Alpha | -1.36 |
| CAGR/Max DD | -0.01 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.373 |
| Beta | 0.164 |
| Beta Downside | 0.626 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.59% |
| Mean DD | 21.44% |
| Median DD | 22.23% |
Description: EUZ Eckert & Ziegler Strahlen November 16, 2025
Eckert & Ziegler SE (XETRA: EUZ) is a Berlin-based specialist that designs, manufactures and distributes isotope-technology components for medical, scientific and industrial applications. The firm operates through two segments – Medical and Isotope Products – and supplies a broad range of items including prostate-cancer seed implants, ruthenium-106 eye applicators, HDR brachytherapy sources, Ga-68 generators, radiopharmaceutical synthesis equipment, high-activity Cs-137 and Co-60 sources, Tc-99m generators, and bulk isotopes for calibration and industrial use.
In FY 2023 the company reported revenue of roughly €1.2 billion, up about 8 % year-on-year, with an operating margin near 12 %. Growth is being driven by rising demand for theranostic isotopes (especially Ga-68 and Lu-177) in oncology, and by tighter regulatory scrutiny that favors established, compliant suppliers for medical radioisotopes. A key sector driver is the expanding global market for brachytherapy, projected to grow at a CAGR of 6-7 % through 2030, supported by aging populations and increasing adoption of minimally invasive cancer treatments.
For a deeper quantitative assessment, the ValueRay platform provides a detailed valuation model and scenario analysis that can help you gauge EUZ’s risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (39.8m TTM) > 0 and > 6% of Revenue (6% = 18.3m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 0.67pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 52.90% (prev 63.84%; Δ -10.94pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 66.5m > Net Income 39.8m (YES >=105%, WARN >=100%) |
| Net Debt (-74.5m) to EBITDA (86.2m) ratio: -0.87 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (62.7m) change vs 12m ago 0.28% (target <= -2.0% for YES) |
| Gross Margin 47.25% (prev 48.08%; Δ -0.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 65.27% (prev 57.75%; Δ 7.52pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 16.94 (EBITDA TTM 86.2m / Interest Expense TTM 3.85m) >= 6 (WARN >= 3) |
Altman Z'' 5.35
| (A) 0.36 = (Total Current Assets 244.6m - Total Current Liabilities 83.5m) / Total Assets 452.0m |
| (B) 0.33 = Retained Earnings (Balance) 147.4m / Total Assets 452.0m |
| (C) 0.14 = EBIT TTM 65.3m / Avg Total Assets 466.5m |
| (D) 0.96 = Book Value of Equity 210.9m / Total Liabilities 218.9m |
| Total Rating: 5.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 83.95
| 1. Piotroski 6.50pt |
| 2. FCF Yield 5.13% |
| 3. FCF Margin 14.54% |
| 4. Debt/Equity 0.20 |
| 5. Debt/Ebitda -0.87 |
| 6. ROIC - WACC (= 9.94)% |
| 7. RoE 17.47% |
| 8. Rev. Trend 93.05% |
| 9. EPS Trend 8.30% |
What is the price of EUZ shares?
Over the past week, the price has changed by +1.94%, over one month by -4.15%, over three months by -14.03% and over the past year by +3.67%.
Is EUZ a buy, sell or hold?
What are the forecasts/targets for the EUZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.9 | 49.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 16 | 4.7% |
EUZ Fundamental Data Overview December 25, 2025
Market Cap EUR = 936.7m (936.7m EUR * 1.0 EUR.EUR)
P/E Trailing = 23.0308
P/S = 3.0766
P/B = 3.9512
Beta = 1.723
Revenue TTM = 304.5m EUR
EBIT TTM = 65.3m EUR
EBITDA TTM = 86.2m EUR
Long Term Debt = 8.72m EUR (from longTermDebt, last quarter)
Short Term Debt = 9.37m EUR (from shortTermDebt, last quarter)
Debt = 46.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -74.5m EUR (from netDebt column, last quarter)
Enterprise Value = 862.2m EUR (936.7m + Debt 46.4m - CCE 121.0m)
Interest Coverage Ratio = 16.94 (Ebit TTM 65.3m / Interest Expense TTM 3.85m)
FCF Yield = 5.13% (FCF TTM 44.3m / Enterprise Value 862.2m)
FCF Margin = 14.54% (FCF TTM 44.3m / Revenue TTM 304.5m)
Net Margin = 13.06% (Net Income TTM 39.8m / Revenue TTM 304.5m)
Gross Margin = 47.25% ((Revenue TTM 304.5m - Cost of Revenue TTM 160.6m) / Revenue TTM)
Gross Margin QoQ = 45.35% (prev 48.87%)
Tobins Q-Ratio = 1.91 (Enterprise Value 862.2m / Total Assets 452.0m)
Interest Expense / Debt = 2.43% (Interest Expense 1.13m / Debt 46.4m)
Taxrate = 38.73% (5.43m / 14.0m)
NOPAT = 40.0m (EBIT 65.3m * (1 - 38.73%))
Current Ratio = 2.93 (Total Current Assets 244.6m / Total Current Liabilities 83.5m)
Debt / Equity = 0.20 (Debt 46.4m / totalStockholderEquity, last quarter 231.5m)
Debt / EBITDA = -0.87 (Net Debt -74.5m / EBITDA 86.2m)
Debt / FCF = -1.68 (Net Debt -74.5m / FCF TTM 44.3m)
Total Stockholder Equity = 227.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.79% (Net Income 39.8m / Total Assets 452.0m)
RoE = 17.47% (Net Income TTM 39.8m / Total Stockholder Equity 227.6m)
RoCE = 27.63% (EBIT 65.3m / Capital Employed (Equity 227.6m + L.T.Debt 8.72m))
RoIC = 16.31% (NOPAT 40.0m / Invested Capital 245.2m)
WACC = 6.38% (E(936.7m)/V(983.1m) * Re(6.62%) + D(46.4m)/V(983.1m) * Rd(2.43%) * (1-Tc(0.39)))
Discount Rate = 6.62% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.22%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈44.1m ; Y1≈54.4m ; Y5≈92.8m
Fair Price DCF = 25.23 (DCF Value 1.58b / Shares Outstanding 62.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 8.30 | EPS CAGR: -15.19% | SUE: N/A | # QB: 0
Revenue Correlation: 93.05 | Revenue CAGR: 11.89% | SUE: 3.39 | # QB: 1
EPS next Year (2026-12-31): EPS=0.82 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-29.2% | Growth Revenue=+5.9%